Avid Bioservices Inc (CDMO)

[Big On Tarvy]

Three Thoughts and a Tidbit:

Registered stock is an attractive way to do a BP partnership. It saves the parties from having to negotiate a separate Registration Rights Agreement. Having a shelf registration in effect allows the Company to raise some cash in the market in April or May if the PPS pops after clinical data is released this spring. It also positions them to do a large BP collaboration at any time.

I was disappointed not to hear today some results from the 1 mg and 3 mg repeat dose HCV cohorts that have finished the 12 week wait. To rationalize the additional month of waiting we now face, I am wondering if the Company wants to wait for the 6 mg cohort to preserve dosing confidentiality. By averaging the results of the top three cohorts they can avoid revealing where the dosing sweet spot is found. Just a wild guess.

Here’s another guess based on better info. I’ll bet SK’s oblique remark today about being able to self-fund some of the Phase II/III trials was a reference to the Cotara GBM trial which is the one product the Company may keep in-house. I still believe the Ph II cancer trials starting next summer will be done through BP alliances finalized after the spring data dump.

Here’s a tidbit I forgot to report on Nov 21:

Q: When are you going to give Bavi its two tradenames for the AC and AV markets?

A: Pharmaceutical companies tend to want to be involved in naming their products.